Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions for maintenance of acid-base balance, isotonicity, and electrophysiological function; dextrose provides calories and may restore blood glucose levels; sodium chloride maintains fluid and electrolyte balance. The combination corrects hypokalemia and dehydration.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Maintenance or replacement of potassium in patients with hypokalemia,Fluid and electrolyte replenishment in patients requiring potassium and sodium,Caloric source for patients needing dextrose
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion at a rate of up to 10 m Eq/h potassium chloride, with typical adult dose of 20-40 m Eq potassium per 1000 m L of solution (e.g., 1 L of this preparation provides 5 m Eq K+). Rate adjusted based on serum potassium and clinical status.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Potassium has a terminal elimination half-life of approximately 3-4 hours in healthy individuals, reflecting rapid renal clearance. However, redistribution and total body potassium turnover are slower (days) due to large intracellular stores. Clinical context: Half-life is prolonged in renal impairment or hypokalemia, and shortened in hyperkalemia.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the Krebs cycle; potassium is excreted primarily by the kidneys; sodium is excreted by the kidneys and sweat.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Potassium is primarily excreted renally (90%) with minor fecal (10%) elimination. In this formulation, dextrose and sodium chloride are fully metabolized or excreted: dextrose undergoes cellular uptake and metabolism; sodium chloride is renally eliminated with sodium reabsorption and chloride as counterion.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Potassium is not significantly protein-bound (<5%). Dextrose and sodium chloride are not bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Potassium Vd is 0.5-0.7 L/kg (approximately 35-50 L in adults), reflecting predominantly intracellular distribution (>98% of body potassium is intracellular). Clinical meaning: Large Vd necessitates loading doses for repletion.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% bioavailability. Not administered orally (100% oral bioavailability for oral potassium salts, but this formulation is IV only).
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia. For GFR 30-60 m L/min, reduce infusion rate and monitor potassium closely; specific dose reduction not defined, use conservative rates (e.g., ≤5 m Eq/h).
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific Child-Pugh based dose adjustment required, but monitor serum potassium as hepatic impairment may affect potassium homeostasis. Use caution in severe hepatic failure.
No dosage adjustment required for hepatic impairment.
Weight-based: 0.5-1 m Eq/kg per day as maintenance, rate not to exceed 0.5 m Eq/kg/h. For this solution (0.037% KCl = 5 m Eq/1000 m L), infusion rate calculated based on desired potassium dose, e.g., 2-4 m L/kg/h for maintenance (providing 0.01-0.02 m Eq/kg/h K+). Monitor serum potassium.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Elderly patients may have reduced renal function; use lower initial infusion rates (e.g., ≤5 m Eq/h) and monitor serum potassium and renal function closely. Avoid in patients with impaired renal function.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Concentrated potassium chloride solutions (not this one; this is a dilute solution) have been associated with fatalities due to maladministration; however, this product is a dilute preparation and does not carry a black box warning.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Use with caution in patients with severe renal impairment, cardiac disease, or hyperkalemia,Monitor serum potassium levels and renal function,Rapid infusion may cause hyperkalemia and cardiac arrhythmias,Contains dextrose; caution in patients with glucose intolerance,Not for rapid correction of severe hypokalemia
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperkalemia,Severe renal impairment (oliguria, anuria),Addison's disease,Hypersensitivity to any component
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No direct food interactions with this intravenous solution. However, patients should avoid excessive dietary potassium (bananas, oranges, tomatoes, potatoes, spinach, nuts, avocados) and salt substitutes containing potassium chloride to prevent hyperkalemia. Sodium intake may need monitoring; avoid high-sodium foods if salt restriction is indicated.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Potassium chloride, as an electrolyte supplement, has no known teratogenic risk. Dextrose and sodium chloride are physiologic. No fetal risks identified in any trimester.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Compatible with breastfeeding. Potassium, dextrose, and sodium chloride are normal components of breast milk. No M/P ratio available; levels are physiologic and not expected to cause adverse effects in infants.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No dose adjustments required specifically for pregnancy. Administer based on maternal electrolyte deficits, volume status, and glucose requirements. Increased intravascular volume in pregnancy may alter distribution, but standard clinical dosing is appropriate.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This solution provides 0.037% potassium chloride (5.0 m Eq/L K+), 5% dextrose (50 g/L), and 0.33% sodium chloride (56 m Eq/L Na+). Use with caution in patients with renal impairment, hyperkalemia, or conditions predisposing to hyperkalemia (e.g., adrenal insufficiency, potassium-sparing diuretics). Rapid infusion may cause hyperkalemia and cardiac arrhythmias. Monitor serum potassium, glucose, and sodium levels. Not for dilution or as a vehicle for drugs incompatible with dextrose or electrolytes.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This infusion contains potassium, dextrose (sugar), and salt. It is given to correct or prevent electrolyte and fluid imbalances.,Tell your healthcare provider if you have kidney disease, diabetes, or are on a potassium-restricted or low-sodium diet.,Report any symptoms such as muscle weakness, irregular heartbeat, numbness, or tingling, which may indicate potassium imbalance.,This solution provides calories from dextrose; monitor blood glucose if you have diabetes.,Avoid consuming potassium-rich foods (bananas, oranges, potatoes, spinach) or salt substitutes without medical advice while receiving this infusion.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions for maintenance of acid-base balance, isotonicity, and electrophysiological function; dextrose provides calories and may restore blood glucose levels; sodium chloride maintains fluid and electrolyte balance. The combination corrects hypokalemia and dehydration.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is: Intravenous infusion at a rate of up to 10 m Eq/h potassium chloride, with typical adult dose of 20-40 m Eq potassium per 1000 m L of solution (e.g., 1 L of this preparation provides 5 m Eq K+). Rate adjusted based on serum potassium and clinical status.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, as an electrolyte supplement, has no known teratogenic risk. Dextrose and sodium chloride are physiologic. No fetal risks identified in any trimester.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.